Epstein–Barr virus infection and nasopharyngeal carcinoma
Authors:
- Francesco PerriFrancesco Perri
- Giuseppina Della Vittoria ScarpatiGSGiuseppina Della Vittoria Scarpati
- Mario GiulianoMGMario Giuliano
- Carmine D’aNielloCDCarmine D’aNiello
- Antonio GnoniAGAntonio Gnoni
- Carla CavaliereCCCarla Cavaliere
- Antonella LicchettaALAntonella Licchetta
- Salvatore PiscontiSPSalvatore Pisconti
- 1 November 2015
- journal article
- review article
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 26 (10) , 1017-1025
Abstract
Oncogenic viruses may have a significant impact on the therapeutic management of several malignancies besides their well-known role in tumor pathogenesis. Epstein-Barr virus (EBV) induces neoplastic transformation of epithelial cells of the nasopharynx by various molecular mechanisms mostly involving activation of oncogenes and inactivation of tumor-suppressor genes. EBV infection can also induce the expression of several immunogenic peptides on the plasma membrane of the infected cells. Importantly, these virus-related antigens may be used as targets for antitumor immunotherapy-based treatment strategies. Two different immunotherapy strategies, namely adoptive and active immunotherapy, have been developed and strongly improved in the recent years. Furthermore, EBV infection may influence the use of targeted therapies for nasopharyngeal carcinoma (NPC) considering that the presence of EBV can induce important modifications in cell signaling. As an example, latent membrane protein type 1 is a viral transmembrane protein mainly involved in the cancerogenesis process, which can also mediate overexpression of the epidermal growth factor receptor (EGFR) in NPC cells, rendering them more sensitive to anti-EGFR therapy. Finally, EBV may induce epigenetic changes in the infected cells, such as DNA hypermethylation and histone deacetylation, that can sustain tumor growth and can thus be considered potential targets for novel therapies. In conclusion, EBV infection can modify important biological features of NPC cells, rendering them more vulnerable to both immunotherapy and targeted therapy.Keywords
This publication has 64 references indexed in Scilit:
- Oncogenic Viruses and Hepatocellular CarcinomaClinics in Liver Disease, 2015
- Kaposi Sarcoma–Associated Herpesvirus-Associated Malignancies: Epidemiology, Pathogenesis, and Advances in TreatmentSeminars in Oncology, 2015
- Aberrant gene promoter methylation of p16, FHIT, CRBP1, WWOX, and DLC-1 in Epstein–Barr virus-associated gastric carcinomasMedical Oncology, 2015
- The Epstein–Barr virus and the pathogenesis of lymphomaThe Journal of Pathology, 2014
- Viruses in cancer treatmentClinical and Translational Oncology, 2012
- Head and Neck CancersJournal of the National Comprehensive Cancer Network, 2011
- Human Papillomavirus and Survival of Patients with Oropharyngeal CancerNew England Journal of Medicine, 2010
- The prognostic significance of tumor vascular invasion and its association with plasma Epstein-Barr virus DNA, tumor volume and metabolic activity in locoregionally advanced nasopharyngeal carcinomaOral Oncology, 2008
- Laboratory markers of tumor burden in nasopharyngeal carcinoma: A comparison of viral load and serologic tests for Epstein‐Barr virusInternational Journal of Cancer, 2004
- Epstein-Barr virus—recent advancesThe Lancet Infectious Diseases, 2003